Research Article
Effects of Xuefu Zhuyu Granules on Patients with Stable Coronary Heart Disease: A Double-Blind, Randomized, and Placebo-Controlled Study

Yuzhen Li, Tianqi Tao, Dandan Song, Tao He, and Xiuhua Liu

Department of Pathophysiology, Graduate School, PLA General Hospital, 100853 Beijing, China

Correspondence should be addressed to Xiuhua Liu; xiuhuali98@163.com

Received 7 August 2020; Revised 26 October 2020; Accepted 20 May 2021; Published 16 July 2021

Academic Editor: Janusz Gebicki

Copyright © 2021 Yuzhen Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Despite advances in the drug treatment strategy for stable coronary heart disease (CHD), the mortality of CHD continues to rise. New or adjuvant treatments would be desirable for CHD. Xuefu Zhuyu granules are derived from the formula of traditional Chinese medicine. To determine whether Xuefu Zhuyu granules might have adjuvant effects on stable CHD, we conducted a controlled clinical trial. Patients with stable CHD were enrolled and randomly assigned to receive Xuefu Zhuyu granules or placebo for 12 weeks in addition to their standard medications for the treatment of CHD. The primary endpoints comprise the Canadian Cardiovascular Society Angina Grading Scale (CCS class), echocardiographic measures, Seattle Angina Questionnaire (SAQ), and coronary artery CT. The secondary endpoints included the parameters of nailfold capillary measurement and cutaneous blood perfusion (CBP). After 12 weeks of follow-up, there was a great improvement of the Canadian Cardiovascular Society Angina Grading Scale (CCS class) in the Xuefu Zhuyu group compared with the placebo group ($p < 0.01$). Also, a decrease was found in the percentage of patients with CCS class II in the Xuefu Zhuyu group between follow-up at 12 weeks and baseline ($p < 0.01$). We observed a significant increase in SAQ scores of physical limitation ($p < 0.01$) and treatment satisfaction ($p < 0.05$) in patients receiving Xuefu Zhuyu treatment at 12 weeks in comparison with those at baseline, but not in placebo treatment ($p > 0.05$). Amelioration in coronary artery stenosis in the Xuefu Zhuyu group was noted ($p < 0.05$). Xuefu Zhuyu granule treatment led to great improvements in cutaneous blood perfusion at follow-up of 12 weeks compared with placebo ($p < 0.05$). These findings suggest that on a background of standard medications, Xuefu Zhuyu granules have the ability to further improve the prognosis of patients with stable CHD.

1. Introduction

With the aging of the world population and the increase in younger patients, coronary heart disease (CHD) is becoming a public health problem. According to the guidelines on the prevention and treatment of CHD, nitrates, β-blocker, calcium channel blocker, anticoagulant, and lipid-lowering medications are standard and first-line treatments for CHD [1, 2]. However, the mortality of CHD resulting from this condition continues to rise all over the world [3, 4]. Thus, new or adjuvant treatments would be desirable for CHD. One such treatment is traditional Chinese medicine (TCM). CHD is a narrowing of the small blood vessels that supply blood and oxygen to the heart [5, 6]. From the viewpoint of TCM, the major causes of CHD are Qi stagnation and blood stasis [7]. Therefore, regulating Qi and promoting blood circulation might be effective strategies in the management of CHD.

Xuefu Zhuyu granules are derived from the TCM formula of the Qing Dynasty in China. They can modulate Qi and stimulate blood circulation [8]. Xuefu Zhuyu granules are extracted from 11 types of herbs, including radix rehmanniae, angelica, radix paeoniae rubra, rhizoma ligustici wallichii, semen persicae, safflower, Bupleurum, liquorice, Platycodon grandiflorum, fructus aurantii immaturus, and Achyranthes [9, 10]. Radix paeoniae rubra, safflower, and fructus aurantii immuturus are the principal pharmacologically active components [10]. Although some studies suggest
the alleviated effect of Xuefu Zhuyu granules on unstable angina [11, 12], its role in the systemic endpoints of stable CHD is still unknown.

The present study evaluated the effects of Xuefu Zhuyu granules in patients with stable CHD. The primary endpoints consisted of the Canadian Cardiovascular Society Angina Grading Scale (CCS class), echocardiographic measures (chamber dimensions, ejection fraction), Seattle Angina Questionnaire (SAQ), and coronary artery CT. The secondary endpoints included the parameters of nailfold capillary measurement and cutaneous blood perfusion, clotting time, and blood lipids.

2. Materials and Methods

2.1. Study Design. This study was a single-center, placebo-controlled, and randomized double-blinded trial that assessed the effect of Xuefu Zhuyu granules on patients with stable CHD. The principal investigator designed the study. The investigators were blinded to the assigned Xuefu Zhuyu granule treatment. The study was conducted in accordance with the guidelines of the Declaration of Helsinki. And the Ethics Committees of PLA General Hospital and Xiyuan Hospital approved the study protocol. Each patient provided written informed consent.

2.2. Study Patients. A total of 40 patients diagnosed with stable CAD were recruited from the PLA General Hospital and Xiyuan Hospital. The basic parameters of the studied subjects are presented in Table 1. The clinical diagnosis of stable CAD was made according to a clinical evaluation, echocardiography, and coronary artery CT. Patients who satisfied the following inclusion criteria were subsumed in the study: (1) less than or equal to 75 years old, (2) a diameter stenosis of main coronary artery 50% to 75% or a diameter stenosis of coronary collateral branch 50% to 100%, and (3) New York Heart Association (NYHA) functional class of I to II. Exclusion criteria included patients undergoing coronary bypass surgery; patients with other relevant medical comorbidities including malfunction of the liver and kidney, diabetes, poor blood pressure control (>160/100 mmHg), hematopoietic diseases, and cancer; and those participating in other clinical trials.

The participants were randomly assigned to receive Xuefu Zhuyu granules or placebo granules twice daily for 12 weeks in addition to their medications prescribed for CHD by the attending physicians. All examinations including echocardiography, coronary artery CT, capillary observation, and blood sample tests were performed at baseline and after 12 weeks.

2.3. The Primary Endpoints. The primary endpoints were the Canadian Cardiovascular Society Angina Grading Scale (CCS class), echocardiographic measures (chamber dimensions, ejection fraction), Seattle Angina Questionnaire (SAQ), and coronary artery CT.

SAQ is a 19-item questionnaire that includes five perspectives: angina stability, angina frequency, physical limitation, treatment satisfaction, and quality of life. Scores range from 0 to 100, with higher scores indicating fewer symptoms and better health status [13, 14].

2.4. The Secondary Endpoints. The secondary endpoints included the parameters of nailfold capillary measurement and cutaneous blood perfusion.

Nailfold capillary measurement was done by videocapillaroscopy. Patients had a seated rest inside the building for 15 min before nailfold capillary measurement was conducted. The temperature of the examination room was 22–24°C. The nailfold (distal row) of the fourth finger of the left hand was examined in each patient. The two operators were responsible for blindly performing nailfold capillary measurement in each patient by employing an optical videocapillaroscopy equipped with magnification 100x contact lens and connected to image analysis software (Tongren Medical Electronics Technology Co., Ltd., China). The images were analyzed by another investigator in a blind manner.

The mean capillary number for each patient was calculated as the arithmetic mean of visible capillaries in three contiguous microscopic fields per mm² [15].

Laser Doppler flowmetry (LDF, Periflux System 5000 equipped with a thermostatic probe, Perimed AB) was employed to detect toe cutaneous blood perfusion (CBP). CBP was evaluated both at basal skin temperature and after probe heating at 44°C (CBP 44°C). And the percentage of CBP 44°C/CBP was calculated.

2.5. The Safety Assessments. The safety assessments included the reports of vital signs, blood, urine, and stool routine examinations, liver function and kidney function, bleeding points, ecchymosis, and adverse events.

Venous blood was drawn between 7 and 10 A.M. after an overnight fast. Blood samples were collected into serum separator tubes. Samples were allowed to clot for 20 min and then centrifuged at 3500 rpm and 4°C for 7 min to obtain serum. Clinical biochemistry parameters were assessed including liver function and kidney function by clinical standard methods.

2.6. Statistical Analysis. All statistical analyses were performed with SPSS software, version 11.0. Continuous variables are presented as the mean ± standard deviation (SD). Categorical data are shown as absolute numbers and percentages. The two-group differences were compared using a 2-sample Student test for continuous variables and a chi-squared test or Wilcoxon test. And the within-group differences were analyzed employing the Wilcoxon paired signed-rank test. A p value < 0.05 was considered statistically significant.

3. Results

3.1. Subject Characteristics. A total of 40 cases were included in the present study. The baseline characteristics of the studied subjects are shown in Table 1. The average course of CHD was 60.72 months. The medium age of the total subjects was 58.03 years old. 75% were male, and 25% were female. The distributions of the baseline characteristics between the
Table 1: Baseline characteristics of stable CHD patients receiving Xuefu Zhuyu granules or placebo.

|                               | Placebo group (n = 20) | Xuefu Zhuyu group (n = 20) | All (n = 40)   |
|-------------------------------|------------------------|----------------------------|---------------|
| Course of disease (months)    | 52.13 ± 38.12          | 69.78 ± 51.69              | 60.72 ± 45.48 |
| Demographics                  |                        |                            |               |
| Age (years)                   | 60.00 ± 6.63           | 56.05 ± 9.86               | 58.03 ± 8.53  |
| Male, n (%)                   | 15 (75)                | 15 (75)                    | 30 (75)       |
| Female, n (%)                 | 5 (25)                 | 5 (25)                     | 10 (25)       |
| Race                          |                        |                            |               |
| Han                           | 19                     | 20                         | 39            |
| Other                         | 1                      | 0                          | 1             |
| Smoking habit, n (%)          | 6 (30)                 | 5 (25)                     | 11 (27.5)     |
| Alcohol consumption, n (%)    | 9 (45)                 | 8 (40)                     | 17 (42.5)     |
| Body mass index (kg/m²)       | 26.10 ± 3.84           | 26.79 ± 3.14               | 26.45 ± 3.47  |
| History of diabetes, n (%)    | 1 (5)                  | 1 (5)                      | 2 (5)         |
| Family history of CHD         | 3                      | 5                          | 8             |
| Abnormal blood routine, n (%) | 4/19 (21.1)            | 5/20 (25)                  | 9/39 (23.1)   |
| Abnormal urine routine, n (%) | 8/19 (42.1)            | 7/20 (35)                  | 15/39 (38.5)  |
| Abnormal stool routine, n (%) | 1/13 (7.7)             | 0/16 (0)                   | 1/29 (3.4)    |
| Abnormal liver function, n (%)| 2/19 (10.5)            | 1/20 (5)                   | 3/39 (7.7)    |
| Abnormal kidney functions, n (%)| 0/19 (0)              | 1/20 (5)                   | 1/39 (2.6)    |
| CCS, n (%)                    |                        |                            |               |
| 0                             | 0 (0)                  | 0 (0)                      | 0 (0)         |
| I                             | 10 (50)                | 12 (60)                    | 22 (55)       |
| II                            | 10 (50)                | 8 (40)                     | 18 (45)       |
| SAQ                           |                        |                            |               |
| Physical limitations          | 63.89 ± 11.58          | 63.67 ± 13.53              | 63.78 ± 12.43 |
| Anginal stability             | 53.75 ± 16.77          | 50.00 ± 18.14              | 51.88 ± 17.35 |
| Anginal frequency             | 82.50 ± 15.52          | 81.50 ± 10.89              | 82.00 ± 13.24 |
| Treatment satisfaction        | 86.18 ± 11.49          | 80.00 ± 19.59              | 83.09 ± 16.16 |
| Disease perception            | 53.75 ± 18.23          | 55.00 ± 25.99              | 54.38 ± 22.17 |
| Echocardiography measurements |                        |                            |               |
| LVEF                          | 0.64 ± 0.05            | 0.63 ± 0.06                | 0.63 ± 0.06   |
| LVED (mm)                     | 46.06 ± 3.49           | 48.25 ± 5.30               | 47.21 ± 4.61  |
| Number of vessel stenosis*    |                        |                            |               |
| Coronary 4-vessel stenosis    | 0 (0)                  | 4 (44.44)                  | 4 (22.22)     |
| Coronary 3-vessel stenosis    | 2 (22.22)              | 1 (11.11)                  | 3 (16.67)     |
| Coronary 2-vessel stenosis    | 3 (33.33)              | 2 (22.22)                  | 5 (27.78)     |
| Coronary 1-vessel stenosis    | 4 (44.44)              | 2 (22.22)                  | 6 (33.33)     |
| Coronary 0-vessel stenosis    | 0 (0)                  | 0 (0)                      | 0 (0)         |
| Medication                    |                        |                            |               |
| Aspirin                       | 4 (20)                 | 9 (45)                     | 13 (32.5)     |
| Clopidogrel                   | 0 (0)                  | 0 (0)                      | 0 (0)         |
| Beta-blocker                  | 3 (15)                 | 5 (25)                     | 8 (20)        |
| Calcium-channel blocker       | 8 (40)                 | 6 (30)                     | 14 (35)       |
| Angiotensin receptor blockers | 5 (25)                 | 9 (45)                     | 14 (35)       |
| ACE inhibitor or ARB          | 2 (10)                 | 4 (20)                     | 6 (15)        |
| Nitrate                       | 3 (15)                 | 4 (20)                     | 7 (17.5)      |

* n = 9.
Xuefu Zhuyu group and the placebo group were well balanced and homogeneous.

3.2. Effects of Xuefu Zhuyu Granules on CCS Class in Patients with Stable CHD. After 12 weeks of follow-up, in the Xuefu Zhuyu group, 100% of patients showed CCS I. However, in the placebo group, 52.94% and 47.06% of patients showed, respectively, CCS I and CCS II. There was a great improvement of CCS angina classes in the Xuefu Zhuyu group compared with the placebo group ($p < 0.01$) (Figure 1). Also, we observed a significant decrease in the percentage of patients with CCS class II in the Xuefu Zhuyu group (from 40% at baseline to 0% at 12 weeks, $p < 0.01$). No significant change in the percentage of patients with CCS class II was detected in the placebo group (from 50% to 47.06%, $p > 0.05$) (Figure 1).

3.3. Effects of Xuefu Zhuyu Granules on SAQ in Patients with Stable CHD. SAQ is a 19-item questionnaire measuring five domains of health status related to coronary artery disease: physical limitation, angina stability, angina frequency, treatment satisfaction, and disease perception. After 12 weeks of treatment, there were no significant differences in the SAQ scores of five domains between the Xuefu Zhuyu group and the placebo group (Figure 2). Furthermore, we analyzed the differences in the SAQ scores between follow-up at 12 weeks and baseline (Figure 2). We observed a significant increase in the SAQ scores of all five domains in patients who underwent Xuefu Zhuyu treatment at 12 weeks in comparison with those at baseline (physical limitation: $72.22 \pm 8.82$ vs. $63.67 \pm 13.53$, $p \leq 0.001$; angina stability: $81.25 \pm 24.16$ vs. $50.00 \pm 18.14$, $p \leq 0.001$; angina frequency: $93.00 \pm 14.55$ vs. $82.50 \pm 19.59$, $p < 0.05$; treatment satisfaction: $90.00 \pm 6.36$ vs. $80.00 \pm 19.59$, $p < 0.05$; and disease perception: $73.33 \pm 20.52$ vs. $55.00 \pm 25.99$, $p < 0.01$). In contrast, in the placebo group, the SAQ scores at 12 weeks were higher only in angina frequency ($92.35 \pm 9.70$ vs. $82.50 \pm 15.52$, $p < 0.01$), and disease perception ($70.10 \pm 17.19$ vs. $53.75 \pm 18.23$, $p \leq 0.001$).

### Table 1: The changes of CCS class in patients receiving Xuefu Zhuyu or placebo granules.

| CCS   | Placebo group | Xuefu Zhuyu group | p value |
|-------|---------------|-------------------|---------|
| 0     | 0 (0%)        | 0 (0%)            |         |
| I     | 10 (50%)      | 9 (52.94%)        | 1.000   |
| II    | 10 (50%)      | 8 (47.06%)        | 0 (0%)  |

### Figure 1: The changes of CCS class in patients receiving Xuefu Zhuyu or placebo granules.

### Figure 2: The changes of SAQ in patients receiving Xuefu Zhuyu or placebo granules: (a) physical limitations; (b) anginal stability; (c) anginal frequency; (d) treatment satisfaction; (e) disease perception. $* p < 0.05$, $** p < 0.01$, and $*** p < 0.001$. SAQ: Seattle Angina Questionnaire.
than those at baseline. There were no significant differences between follow-up at 12 weeks and baseline with respect to improvement in physical limitation (66.41 ± 10.85 vs. 63.89 ± 11.58, \(p > 0.05\)) or treatment satisfaction (87.89 ± 7.63 vs. 86.18 ± 11.49, \(p > 0.05\)).

### 3.4. Effects of Xuefu Zhuyu Granules on Echocardiographic Parameters and CTA in Patients with Stable CHD

Echocardiographic analyses showed that no significant improvement in LVEF and LVED was noted in the Xuefu Zhuyu group. The percentage of coronary artery stenosis was not different between the Xuefu Zhuyu group and the placebo group (\(p > 0.05\)). Further analysis showed that a significant difference in coronary artery stenosis was noted between baseline and follow-up at 12 weeks in the Xuefu Zhuyu group (\(p < 0.05\)) (Table 2).

### 3.5. Effects of Xuefu Zhuyu Granules on the Parameters of Nailfold Capillaries in Patients with Stable CHD

The number and diameter of nailfold capillaries were detected using videocapillaroscopy. As shown in Figure 3, there were no significant differences in the number and diameter of nailfold capillaries between the Xuefu Zhuyu group and the placebo group at baseline and 12 weeks. To further analyze the changes of capillary parameters, we compared the number and diameter of nailfold capillaries at baseline with that at 12 weeks. And we found that the number of capillaries at 12 weeks (5.56 ± 0.81) was more than that at baseline (4.93 ± 1.24) (\(p < 0.01\)) in patients treated with Xuefu Zhuyu granules, but not in the placebo patients (\(p > 0.05\)).

### 3.6. Effects of Xuefu Zhuyu Granules on Cutaneous Blood Perfusion in Patients with Stable CHD

Cutaneous blood perfusion is one of the critical indexes reflecting capillary function. As shown in Figure 4, cutaneous blood perfusion did not differ between the two groups at baseline. Xuefu Zhuyu granule treatment led to significant improvements in CBP 44°C and CBP 44°C/CBP at follow-up of 12 weeks compared with placebo (CBP 44°C: 172.60 ± 44.57 vs. 114.00 ± 36.70, \(p < 0.01\); CBP 44°C/CBP: 765.50 ± 358.96 vs. 451.10 ± 213.64, \(p < 0.05\)).

### 3.7. Safety Endpoints

The safety assessments are shown in Table 3. Vital signs of all patients were recorded at each study visit. There were no statistically significant differences between the placebo and treatment groups (\(p > 0.05\)). We compared the intergroup and intragroup differences in abnormal percentages of blood routine, urine routine, stool routine, and liver and kidney functions between the placebo and treatment groups. These abnormal percentages did not show great differences. Also, bleeding points, ecchymosis, and serious adverse events did not occur in patients receiving Xuefu Zhuyu or placebo after 12 weeks.
4. Discussion

Stable CHD as a public health problem is still an extremely important focus of clinical cardiology despite the use of medicaments such as β-blocker; calcium channel blocker improves the symptoms of stable CHD patients [1, 2, 16]. High morbidity and mortality all over the world ask for us to seek other novel therapeutic approaches to further improve the prognosis for patients with stable CHD. TCM has widely been used to effectively treat various heart diseases including chronic heart failure, hypertension, and cardiac hypertrophy [17]. According to the theory of TCM, the occurrence of stable CHD is due to the disturbance of Qi and blood. Therefore, regulation of Qi and blood is critical for patients with stable CHD.

Xuefu Zhuyu has the ability to modulate Qi and blood [8]. And it has been widely applied to stable CHD in the clinic. However, we employ PubMed to search Xuefu Zhuyu

| Placebo group (n = 10) | Xuefu Zhuyu group (n = 10) | p value |
|------------------------|-----------------------------|---------|
| CBP (PU)               |                             |         |
| Baseline               | 25.20±12.39                 |         |
| 12 weeks               | 23.80±11.47                 | 0.666   |
| Baseline               | 20.9±13.99                  |         |
| 12 weeks               | 23.50±12.44                 | 0.956   |
| CBP 44°C (PU)          |                             |         |
| Baseline               | 123±48.94                   |         |
| 12 weeks               | 114.00±36.70                | 0.005   |
| Baseline               | 134.8±70.24                 |         |
| 12 weeks               | 172.60±44.57                | 0.029   |
| CBP 44°C/CBP (%)       |                             |         |
| Baseline               | 470.9±306.19                |         |
| 12 weeks               | 451.10±213.64               | 0.029   |

**Figure 4:** The changes of cutaneous blood perfusion in patients receiving Xuefu Zhuyu or placebo granules: (a) cutaneous blood perfusion (CBP); (b) cutaneous blood perfusion after probe heating at 44°C (CBP 44°C); (c) CBP 44°C/CBP. *p < 0.05, **p < 0.01.

| Vital signs          | Placebo group (n = 20) | 12 weeks (n = 17) | p value | Xuefu Zhuyu group (n = 20) | 12 weeks (n = 20) | p value |
|----------------------|------------------------|-------------------|---------|-----------------------------|-------------------|---------|
| Temperature (°C)     | 36.60 ± 0.23           | 36.48 ± 0.26      | 0.025   | 36.51 ± 0.21                | 36.45 ± 0.24      | 0.323   |
| Breath               | 19.20 ± 1.28           | 18.71 ± 1.21      | 0.134   | 18.75 ± 1.33                | 18.55 ± 1.39      | 0.530   |
| Pulse rate           | 70.70 ± 8.59           | 68.53 ± 6.37      | 0.439   | 74.05 ± 10.99               | 70.50 ± 9.46      | 0.274   |
| Heart rate (bpm)     | 68.88 ± 9.10           | 65.64 ± 7.45      | 0.599   | 71.50 ± 10.31               | 68.47 ± 9.72      | 0.698   |
| Systolic BP (mmHg)   | 127.55 ± 16.37         | 133.76 ± 13.23    | 0.112   | 125.90 ± 12.62              | 131.30 ± 13.51    | 0.083   |
| Diastolic BP (mmHg)  | 80.63 ± 10.03          | 84.59 ± 10.15     | 0.021   | 80.50 ± 7.97                | 84.80 ± 10.10     | 0.035   |
| Abnormal blood routine (%) | 10.5                  | 17.6              | 0.655   | 25                           | 30                | 0.705   |
| Abnormal urine routine (%) | 42.1                  | 41.2              | 1.000   | 35                           | 44.4              | 0.414   |
| Abnormal stool routine (%) | 7.1                   | 12.5              | 1.000   | 0                            | 0                 | 1.000   |
| Abnormal liver function (%) | 10.5                  | 5.9               | 0.564   | 5                            | 10                | 0.564   |
| Abnormal kidney function (%) | 0                    | 0                 | 1.000   | 5                            | 10                | 0.317   |
| Bleeding point (%)   | 0                      | 0                 | 0       | 0                            | 0                 | 0       |
| Ecchymosis (%)       | 0                      | 0                 | 0       | 0                            | 0                 | 0       |
| Serious adverse events |                       |                   |         |                              |                   |         |
| Death                | 0                      | 0                 | 0       | 0                            | 0                 | 0       |
| Hospitalization      | 0                      | 0                 | 0       | 0                            | 0                 | 0       |
| Worsening CHD        | 0                      | 0                 | 0       | 0                            | 0                 | 0       |
| Stroke               | 0                      | 0                 | 0       | 0                            | 0                 | 0       |
| Unknown reason       | 0                      | 0                 | 0       | 0                            | 0                 | 0       |

Table 3: The safety endpoints of stable CHD patients receiving Xuefu Zhuyu granules or placebo after 12 weeks.
and find that there are 11 publications for the effects of Xuefu Zhuyu on patients with CHD. Among them, only 2 publications focus on stable angina pectoris. One reports that Xuefu Zhuyu could improve the levels of octadecanoic acid, phosphoglycerol, and sphingomyelin [18]. Another is published by our group, which indicates that 2-deoxy-D-glucose and spermine might constitute the partial material foundation of Qi in CHD patients treated with Xuefu Zhuyu [19]. Thus, the efficacy and safety of Xuefu Zhuyu in patients with stable CHD need to be confirmed systematically. In the present study, a double-blind, randomized, and placebo-controlled method is used to detect the effects of Xuefu Zhuyu on the primary endpoints of stable CHD patients. Among the primary endpoints, our study demonstrates that Xuefu Zhuyu granules decrease CCS angina class and increase the SAQ primary endpoints of stable CHD patients. Among the primary endpoints, our study demonstrates that Xuefu Zhuyu granules decrease CCS angina class and increase the SAQ scores of physical limitation and treatment satisfaction. But chamber dimensions and ejection fraction by echocardiographic measures do not show a significant improvement in the Xuefu Zhuyu group compared with the placebo group. A plausible reason is that the chamber dimensions and ejection fraction of enrolled patients are in the normal range. In addition, we find a difference in the percentage of coronary artery stenosis between baseline and 12-week follow-up. Because only 9 patients agree to do the CTA test, the improvement result needs to be further confirmed in a large sample.

Abnormalities in the structure and function of the coronary microcirculation could serve as important markers of CHD [5, 20]. The coronary microvasculature cannot be directly imaged in vivo [21]. Some invasive and noninvasive techniques are employed to assess coronary microvascular function [22]. However, due to the invasiveness, radioactivity, investigational and technical limitations, and costs, it is not easy to observe clinically at all times to accurately monitor the efficacy [20, 21]. It has been demonstrated that peripheral microvascular function reflects coronary vascular function [22]. Nailfold capillary and LDF measurements are noninvasive, continuous, and real-time quantitative methods for peripheral microvascular function [23, 24]. Therefore, we use the two methods to detect the changes of nailfold capillaries and cutaneous blood perfusion as secondary endpoints. The results of our study suggest that Xuefu Zhuyu granules significantly increase the number of nailfold capillaries. It is reported that capillary density may positively affect tissue perfusion [25, 26]. It seems that Xuefu Zhuyu granules can induce an elevation in tissue perfusion. Indeed, our LDF study indicates that Xuefu Zhuyu granules are able to greatly improve cutaneous blood perfusion.

It has been reported that the abnormality of the substrate and energy metabolism is fundamental in the development of CHD [27]. Our previous study analyzed the metabolic profiling of CHD patients undergoing Xuefu Zhuyu granules. We found that 2-deoxy-D-glucose and spermine might constitute the partial material foundation of Qi in CHD patients treated with Xuefu Zhuyu granules [19]. There is evidence that Xuefu Zhuyu decoction decreases the levels of soluble VCAM-1 and soluble ICAM-1 in serum of patients with unstable angina pectoris [28, 29]. Oxidative stress response has been demonstrated to be an independent risk for the development of CHD. A recent study reports that Xuefu Zhuyu decoction could increase the level of superoxide dismutase and reduce the level of malondialdehyde in patients with CHD [30]. It seems that Xuefu Zhuyu has a potential role in inhibiting oxidative stress response. These findings indicate that Xuefu Zhuyu might exert its treatment effects on CHD patient by regulating metabolic profiling, inhibiting the production of adhesive molecules, and improving oxidative stress response.

Although the present study provides beneficial findings, it has some limitations which have to be acknowledged. First, this study is a single-center trial, which limits generalizability. Second, the sample size of the study is small, which might have decreased the ability to detect a treatment effect. Indeed, significant differences in some outcomes are not observed between the Xuefu Zhuyu group and the placebo group. Therefore, further study with a large sample size needs to be done. Third, only one dosage is employed in the study. Two or more dosages should be used to compare the treatment effects. Fourth, all examinations are performed at 12 weeks. The observation duration is relatively short for safety.

5. Conclusions

The results demonstrate that Xuefu Zhuyu granules are able to further ameliorate the prognosis of patients with stable CHD. The findings support that on a background of standard medications, Xuefu Zhuyu granules could be used in combination therapy for stable CHD.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors report no conflict of interests.

Acknowledgments

This work was supported by grants from the National Basic Research Program of China (2015CB554402) and National Natural Science Foundation of China (31971049 and 81970246).

References

[1] S. D. Fihn, J. M. Gardin, J. Abrams et al., “2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,” Journal of the American College of Cardiology, vol. 60, no. 24, pp. e44–e164, 2012.
[2] G. N. Levine, E. R. Bates, J. A. Bittl et al., “2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCP/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACCP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 ACC/AHA Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery,” *Circulation*, vol. 134, no. 10, pp. e123–e155, 2016.

[3] E. J. Benjamin, M. J. Blaha, S. E. Chiuve et al., “Heart disease and stroke statistics-2017 update: a report from the American Heart Association,” *Circulation*, vol. 135, no. 10, pp. e146–e603, 2017.

[4] R. Lozano, M. Naghavi, K. Foreman et al., “Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010,” *Lancet*, vol. 380, no. 9859, pp. 2095–2128, 2012.

[5] A. R. Pries and B. Reglin, “Coronary microcirculatory pathophysiology: can we afford it to remain a black box?,” *European Heart Journal*, vol. 38, no. 7, pp. 478–488, 2017.

[6] G. A. de Waard, S. S. Nijjer, M. A. van Lavieren et al., “Invasive minimal microvascular resistance is a new index to assess microcirculatory function independent of obstructive coronary artery disease,” *Journal of the American Heart Association*, vol. 5, no. 12, article e004482, 2016.

[7] J. N. Zhao, Y. Zhang, X. Lan et al., “Efficacy and safety of Xue-Fu-Zhu-Yu capsule in treating chronic stable angina (qi stagnation and blood stasis syndrome): study protocol for a multicenter, randomized, double-blind, placebo-controlled trial,” *Medicine (Baltimore)*, vol. 98, no. 31, article e16539, 2019.

[8] H. He, G. Chen, J. Gao et al., “Xue-Fu-Zhu-Yu capsule in the treatment of qi stagnation and blood stasis syndrome: a study protocol for a randomised controlled pilot and feasibility trial,” *Trials*, vol. 19, no. 1, p. 515, 2018.

[9] S. Q. Tan, X. Geng, J. H. Liu et al., “Xue-fu-zhu-yu decoction protects rats against retinal ischemia by downregulation of HIF-1α and VEGF via inhibition of RBP2 and PKM2,” *BMC Complementary and Alternative Medicine*, vol. 17, no. 1, p. 365, 2017.

[10] Y. N. Zhou, M. Y. Sun, Y. P. Mu et al., “Xuefuzhuyu decoction inhibits angiogenesis attenuates liver fibrosis induced by CCl₄ in mice,” *Journal of Ethnopharmacology*, vol. 153, no. 3, pp. 659–666, 2014.

[11] J. Wang, X. Yang, F. Chu et al., “The effects of xuefu zhuyu and shengmai on the evolution of syndromes and inflammatory markers in patients with unstable angina pectoris after percutaneous coronary intervention: a randomised controlled clinical trial,” *Evidence-based Complementary and Alternative Medicine*, vol. 2013, Article ID 896467, 9 pages, 2013.

[12] F. Y. Chu, J. Wang, K. W. Yao, and Z. Z. Li, “Effect of Xuefu Zhuyu capsule (血府逐瘀胶囊) on the symptoms and signs and health-related quality of life in the unstable angina patients with blood-stasis syndrome after percutaneous coronary intervention: a randomized controlled trial,” *Chinese Journal of Integrative Medicine*, vol. 16, no. 5, pp. 399–405, 2010.

[13] S. Verheyen, E. M. Jolicic, M. W. Behan et al., “Efficacy of a device to narrow the coronary sinus in refractory angina,” *The New England Journal of Medicine*, vol. 372, no. 6, pp. 519–527, 2015.

[14] J. A. Spertus, J. A. Winder, T. A. Dewhurst et al., “Development and evaluation of the Seattle angina questionnaire: a new functional status measure for coronary artery disease,” *Journal of the American College of Cardiology*, vol. 25, no. 2, pp. 333–341, 1995.

[15] R. de Moraes, D. van Bavel, M. B. Gomes, and E. Tibirica, “Effects of non-supervised low intensity aerobic exercise training on the microvascular endothelial function of patients with type 1 diabetes: a non-pharmacological interventional study,” *BMC Cardiovascular Disorders*, vol. 16, no. 1, p. 23, 2016.

[16] J. A. Ladapo, K. S. Goldfeld, and P. S. Douglas, “Projected morbidity and mortality from missed diagnoses of coronary artery disease in the United States,” *International Journal of Cardiology*, vol. 195, pp. 250–252, 2015.

[17] X. Li, J. Zhang, J. Huang et al., “A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure,” *Journal of the American College of Cardiology*, vol. 62, no. 12, pp. 1065–1072, 2013.

[18] X. Y. Lu, H. Xu, T. Zhao, and G. Li, “Study of serum metabolomics and formula-pattern correspondence in coronary heart disease patients diagnosed as phlegm or blood stasis pattern based on ultra performance liquid chromatography mass spectrometry,” *Chinese Journal of Integrative Medicine*, vol. 24, no. 12, pp. 905–911, 2018.

[19] T. Q. Tao, T. He, X. R. Wang, and X. Liu, “Metabolic profiling analysis of patients with coronary heart disease undergoing xuefuzhuyu decoction treatment,” *Frontiers in Pharmacology*, vol. 10, p. 985, 2019.

[20] P. G. Camici, G. d’Amati, and O. Rimoldi, “Coronary microvascular dysfunction: mechanisms and functional assessment,” *Nature Reviews. Cardiology*, vol. 12, no. 1, pp. 48–62, 2015.

[21] J. Herrmann, J. C. Kaski, and A. Lerman, “Coronary microvascular dysfunction in the clinical setting: from mystery to reality,” *European Heart Journal*, vol. 33, no. 22, pp. 2771–2783, 2012.

[22] A. al-Badri, J. H. Kim, C. Liu, P. K. Mehta, and A. A. Quyyumi, “Peripheral microvascular function reflects coronary vascular function,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 39, no. 7, pp. 1492–1500, 2019.

[23] M. Cutolo, C. Ferrone, C. Pizzorni, S. Soldano, B. Seriolo, and A. Sulli, “Peripheral microvascular abnormalities in systemic sclerosis: a laser-Doppler and nailfold videocapillaroscopy study,” *The Journal of Rheumatology*, vol. 37, no. 6, pp. 1174–1180, 2010.

[24] V. Lambrecht, M. Cutolo, F. de Keyser et al., “Reliability of the quantitative assessment of peripheral blood perfusion by laser speckle contrast analysis in a systemic sclerosis cohort,” *Annals of the Rheumatic Diseases*, vol. 75, no. 6, pp. 1263–1264, 2016.

[25] E. H. Serné, R. O. Gans, J. C. ter Maaten, G. J. Tangelder, A. J. M. Donker, and C. D. A. Stehouwer, “Impaired skin capillary recruitment in essential hypertension is caused by both
functional and structural capillary rarefaction,” *Hypertension*, vol. 38, no. 2, pp. 238–242, 2001.

[26] A. J. Bosch, J. M. Harazny, I. Kistner, S. Friedrich, J. Wojtkiewicz, and R. E. Schmieder, “Retinal capillary rarefaction in patients with untreated mild-moderate hypertension,” *BMC Cardiovascular Disorders*, vol. 17, no. 1, p. 300, 2017.

[27] T. Doenst, T. D. Nguyen, and E. D. Abel, “Cardiac metabolism in heart failure: implications beyond ATP production,” *Circulation Research*, vol. 113, no. 6, pp. 709–724, 2013.

[28] B. X. Wang, X. M. Dong, A. M. Guo, and J. Zhang, “Effects of xuefu zhuyu decoction on functions of vascular endothelium in patients with unstable angina pectoris,” *Zhong Xi Yi Jie He Xue Bao*, vol. 4, no. 3, pp. 256–259, 2006.

[29] G. L. Zheng and S. H. Wang, “Clinical effect and mechanisms of xuefu zhuyu capsule in treating unstable angina pectoris,” *Zhongguo Zhong Xi Yi Jie He Za Zhi*, vol. 29, no. 1, pp. 65–68, 2009.

[30] J. Zhao, H. Liu, B. Xu et al., “The role of Xuefu Zhuyu decoction in prevention of contrast-induced nephropathy after percutaneous coronary intervention,” *Evidence-based Complementary and Alternative Medicine*, vol. 2020, Article ID 5419016, 7 pages, 2020.